Buy Alembic Pharmaceuticals, target price Rs 653: ICICI Securities

Synopsis

Alembic Pharmaceuticals, incorporated in the year 2010, is a Mid Cap company (having a market cap of Rs 10695.00 Crore) operating in Pharmaceuticals sector.

Alembic pharmaceuticalsAgencies
Given the recent correction in the stock price (~18% in the past 3 months) and comfortable valuations coupled with prospects of plants getting regulatory nod, the brokerage upgrades the stock to BUY.
has buy call on with a target price of Rs 653.The current market price of Alembic Pharmaceuticals is Rs 544.05.


Alembic Pharmaceuticals, incorporated in the year 2010, is a Mid Cap company (having a market cap of Rs 10695.00 Crore) operating in Pharmaceuticals sector.

Alembic Pharmaceuticals key Products/Revenue Segments include Pharmaceuticals, Export Incentives, Royalty Income and Other Operating Revenue for the year ending 31-Mar-2022.

Financials
For the quarter ended 31-12-2022, the company has reported a Consolidated Total Income of Rs 1509.46 Crore, up 2.31 % from last quarter Total Income of Rs 1475.34 Crore and up 18.57 % from last year same quarter Total Income of Rs 1273.04 Crore. Company has reported net profit after tax of Rs 135.51 Crore in latest quarter.

The company’s top management includes Mr.Chirayu Amin, Mr.Pranav Amin, Mr.Shaunak Amin, Mr.R K Baheti, Mr.K G Ramanathan, Mr.Pranav Parikh, Mr.Paresh Saraiya, Dr.Archana Hingorani, Mr.Ashok Barat. Company has K S Aiyar & Co. as its auditors. As on 31-12-2022, the company has a total of 20 Crore shares outstanding.

Investment Rationale
Given the recent correction in the stock price (~18% in the past 3 months) and comfortable valuations coupled with prospects of plants getting regulatory nod, the brokerage upgrades the stock to BUY (from Add) with a revised target price of Rs653/share (earlier: Rs695).

Promoter/FII Holdings
Promoters held 69.61 per cent stake in the company as of 31-Dec-2022, while FIIs owned 4.99 per cent, DIIs 12.72 per cent.
(Disclaimer: Recommendations given in this section or any reports attached herein are authored by an external party. Views expressed are that of the respective authors/entities. These do not represent the views of Economic Times (ET). ET does not guarantee, vouch for, endorse any of its contents and hereby disclaims all warranties, express or implied, relating to the same. Please consult your financial adviser and seek independent advice.
Experience Your Economic Times Newspaper, The Digital Way!

Read More News on

(What's moving Sensex and Nifty Track latest market news, stock tips and expert advice on ETMarkets. Also, ETMarkets.com is now on Telegram. For fastest news alerts on financial markets, investment strategies and stocks alerts, subscribe to our Telegram feeds.)

Download The Economic Times News App to get Daily Market Updates & Live Business News.

...more
Pick the best stocks for yourself
Powered by
Read before you invest. Insights on Alembic Pharmaceuticals Ltd.. Explore Now